scholarly journals Prescription Patterns of Medications for Alzheimer’s Disease in Japan from 2010 to 2015: A Descriptive Pharmacy Claims Database Study

2016 ◽  
Vol 6 (1) ◽  
pp. 25-37 ◽  
Author(s):  
Kimiko Kadohara ◽  
Izumi Sato ◽  
Yuko Doi ◽  
Masaru Arai ◽  
Yosuke Fujii ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prescription Patterns ◽  
Claims Database ◽  
Database Study ◽  
Pharmacy Claims

scholarly journals Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study

2021 ◽  
Author(s):  
Astrid Gendolla ◽  
Nadine Rauer ◽  
Susanne Kraemer ◽  
Inka Schwerdtner ◽  
Andreas Straube
Keyword(s):  
Prescription Patterns ◽  
Claims Database ◽  
Database Study

P4-163: HEALTH CARE COSTS AMONG NEWLY DIAGNOSED ALZHEIMER'S DISEASE PATIENTS IN A REAL-WORLD ADMINISTRATIVE CLAIMS DATABASE

2006 ◽  
Vol 14 (7S_Part_28) ◽  
pp. P1501-P1502
Author(s):  
Rezaul Karim Khandker ◽  
Richard B. Lipton ◽  
Ellen Thiel ◽  
Matthew Brouillette ◽  
Christopher M. Black
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Care ◽  
Health Care Costs ◽  
Real World ◽  
Administrative Claims ◽  
Newly Diagnosed ◽  
Claims Database ◽  
Care Costs

scholarly journals Anticholinergic and sedative drug burden in community-dwelling older people: a national database study

BMJ Open ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. e022500 ◽  
Author(s):  
Catherine J Byrne ◽  
Caroline Walsh ◽  
Caitriona Cahir ◽  
Cristín Ryan ◽  
David J Williams ◽  
...  
Keyword(s):  
Older People ◽  
Community Dwelling ◽  
National Database ◽  
Older Individuals ◽  
Patient Factors ◽  
Claims Database ◽  
Database Study ◽  
Factors Associated ◽  
Pharmacy Claims ◽  
Sedative Effects

ObjectivesThe Drug Burden Index (DBI) tool quantifies individual exposure to anticholinergic and sedative medications. The DBI has been internationally validated against adverse health outcomes in older people. DBI exposure has not been reported in the Irish older population. This study aimed to: (1) develop a list of drugs with clinically significant anticholinergic and/or sedative effects (DBI medications) relevant to Ireland; (2) examine, using the DBI formula, the prevalence of exposure to DBI medications in Irish older people and (3) explore patient factors associated DBI exposure.DesignA cross-sectional national pharmacy claims database study.SettingCommunity setting using the General Medical Services (GMS) scheme pharmacy claims database maintained by the Health Service Executive Primary Care Reimbursement Services.ParticipantsIrish older individuals (aged ≥65 years) enrolled in the GMS scheme and dispensed at least one prescription item in 2016 (n=428 516).Main outcome measuresPrevalence of exposure to DBI medications and patient factors associated with DBI exposure.Results282 874 (66%) of the GMS population aged ≥65 years were exposed to at least one DBI medication in 2016. Prevalence of exposure to DBI medications was significantly higher in females than males (females 71.6% vs males 58.7%, adjusted OR 1.65, 95% CI 1.63 to 1.68). Prevalence of DBI exposure increased progressively with the number of chronic drugs used, rising from 42.7% of those prescribed 0–4 chronic drugs to 95.4% of those on ≥12 chronic drugs (adjusted OR 27.8, 95% CI 26.7 to 29.0). The most frequently used DBI medications were codeine/paracetamol combination products (20.1% of patients), tramadol (11.5%), zopiclone (9.5%), zolpidem (8.5%), pregabalin (7.9%) and alprazolam (7.8%).ConclusionsThe majority of older people in Ireland are exposed to medications with anticholinergic and/or sedative effects, particularly females and those with multiple comorbidities. The high use of low-dose codeine/paracetamol combination products, Z-drugs and benzodiazepines, suggests there are opportunities for deprescribing.

Sign in / Sign up

Export Citation Format

Share Document